Overview
- Two 2026 systematic reviews that pooled preclinical work and large real‑world studies found no consistent, class‑wide increase in depression, suicidality, or other neuropsychiatric harms from GLP‑1 receptor agonists.
- Multiple large observational analyses reported lower risks of suicide, self‑harm, or psychiatric hospitalization for some GLP‑1 drugs, and a Swedish cohort linked semaglutide use to fewer psychiatric admissions in people with bipolar disorder.
- One obesity‑clinic cohort produced a divergent signal showing markedly higher rates of major depressive disorder, anxiety, and suicidal ideation or attempts among GLP‑1RA users, a finding reviewers say could reflect greater diagnostic capture in specialized settings.
- All human data are observational and rely on ICD codes, claims records, registries, or adverse‑event reports, so they are vulnerable to confounding, comparator choice effects, and surveillance bias and cannot prove benefit or harm.
- Authors and regulators call for prospective randomized trials that use validated continuous mood scales and clearly defined psychiatric hospitalization endpoints so clinicians and patients can make informed safety and treatment decisions.